Drug Profile


Alternative Names: ABI 1648; KRM 1648; PA 1648

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kaneka
  • Developer ActivBiotics
  • Class Antituberculars; Rifamycins
  • Mechanism of Action DNA-directed RNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atherosclerosis; Chlamydial infections; Clostridium-difficile-infections; Helicobacter infections; Intermittent claudication; Leprosy; Mycobacterium avium complex infections; Tuberculosis

Most Recent Events

  • 29 Jan 2018 Discontinued - Preclinical for Clostridium difficile infections in USA (PO) (ActivBiotics website, January 2018)
  • 25 Apr 2013 ActivBiotics completes a phase IIb trial in Chlamydial infections in USA (NCT01631201)
  • 01 Jul 2012 ActivBiotics initiates enrolment in a phase I trial for Chlamydial infections in USA (NCT01631201)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top